NO20063866L - 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. - Google Patents
1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet.Info
- Publication number
- NO20063866L NO20063866L NO20063866A NO20063866A NO20063866L NO 20063866 L NO20063866 L NO 20063866L NO 20063866 A NO20063866 A NO 20063866A NO 20063866 A NO20063866 A NO 20063866A NO 20063866 L NO20063866 L NO 20063866L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazole derivatives
- trisubstituted
- hydro
- antagonistic activity
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53998304P | 2004-01-30 | 2004-01-30 | |
EP04100338 | 2004-01-30 | ||
PCT/EP2005/050339 WO2005074920A1 (fr) | 2004-01-30 | 2005-01-27 | Derives de 4,5-dihydro-1h-pyrazole 1,3,5-trisubstitues presentant une activite antagonistique a cb1 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063866L true NO20063866L (no) | 2006-10-27 |
Family
ID=34839806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063866A NO20063866L (no) | 2004-01-30 | 2006-08-30 | 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1713475B1 (fr) |
JP (1) | JP4693787B2 (fr) |
KR (1) | KR20060131861A (fr) |
CN (1) | CN100563651C (fr) |
AT (1) | ATE402697T1 (fr) |
AU (1) | AU2005210163B2 (fr) |
BR (1) | BRPI0507005A (fr) |
CA (1) | CA2552940A1 (fr) |
DE (1) | DE602005008555D1 (fr) |
DK (1) | DK1713475T3 (fr) |
ES (1) | ES2311972T3 (fr) |
HK (1) | HK1099688A1 (fr) |
HR (1) | HRP20080549T3 (fr) |
IL (1) | IL176547A (fr) |
MX (1) | MXPA06008593A (fr) |
NO (1) | NO20063866L (fr) |
PL (1) | PL1713475T3 (fr) |
PT (1) | PT1713475E (fr) |
RU (1) | RU2360904C2 (fr) |
SI (1) | SI1713475T1 (fr) |
WO (1) | WO2005074920A1 (fr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1745781A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin |
ES2330993B1 (es) * | 2005-07-15 | 2010-07-06 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina. |
ES2348374B1 (es) * | 2005-07-15 | 2011-08-02 | Laboratorios Del Dr Esteve, S.A. | Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos. |
EP1743892A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés pyrazoline substitués, leur préparation et utilisation comme médicaments |
EP1749820A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Sels de dérives pyrazoline, leur préparation et leur utilisation comme medicaments médicaments |
WO2007009699A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Utilisation de composes pyrazoliniques substitues et de leurs derives contre des affections associees au systeme des cannabinoides |
ES2337005B1 (es) * | 2005-07-15 | 2011-01-10 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos. |
EP1910302A1 (fr) * | 2005-07-15 | 2008-04-16 | Laboratorios del Dr. Esteve S.A. | Composes de pyrazoline a substitution carbonyle, preparation de ceux-ci et utilisation de ceux-ci comme modulateurs des recepteurs cb1 |
EP1743642A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composés à base de pyrazoline pour le traitement des maladies associées avec le système cannabinoïde |
ES2327379B1 (es) * | 2005-07-15 | 2010-05-28 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos. |
EP1849776A1 (fr) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de la pyrazoline azépane- ou azocane-substituées, leur préparation et utilisation comme médicaments |
EP1757588A1 (fr) * | 2005-07-29 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Forme polymorphe du N-Piperidinyl-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide et son utilisation comme modulateur du récepteur cannabinoïde |
EP1743890A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments. |
WO2007009682A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Formulations pharmaceutiques orales comprenant des composes de pyrazoline substitues |
EP1745783A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios del Dr. Esteve S.A. | Composés à base de pyrazoline, leur préparation et leur utilisation comme médicaments |
WO2007009720A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve S.A. | Promedicaments de composes de pyrazoline, fabrication et utilisation comme medicaments |
WO2007009690A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Composes de pyrazoline a substitution heterocyclyle, preparation et utilisation de ceux-ci comme medicaments |
EP1749819A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Hydrates de (rac)-N-piperidinyl-5-(4-chlorphenyl)-1-(2,4-dichlorphenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide |
EP1743888A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Composés de pyrazoline subsitués par un groupe carbonyle utiles comme modulateurs du recepteur CB1 |
EP1849784A1 (fr) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de la pyrazoline Indoline-substituée, leur préparation and utilisation comme médicaments |
ES2326952B1 (es) * | 2005-07-15 | 2010-05-28 | Laboratorios Del Dr. Esteve, S.A. | Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida. |
EP1757589A1 (fr) * | 2005-07-29 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Une phase amorphe d`un pyrazoline substitué, sa préparation et son usage comme médicament |
ES2326357B1 (es) * | 2005-07-29 | 2010-04-21 | Laboratorios Del Dr. Esteve, S.A. | Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento. |
WO2007017126A2 (fr) * | 2005-07-29 | 2007-02-15 | Laboratorios Del Dr. Esteve, S.A. | Polymorphe d'une pyrazoline substituee, sa preparation et son utilisation comme medicaments |
EP1911747A1 (fr) | 2006-10-11 | 2008-04-16 | Laboratorios del Dr. Esteve S.A. | Dérivés de pyrazoline substitués par un groupe sulfonamide, leur préparation et leur utlisation comme des modulateurs de CB1 |
ES2330071B1 (es) * | 2007-01-15 | 2010-07-05 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas. |
ES2328653B1 (es) * | 2007-01-15 | 2010-05-28 | Laboratorios Del Dr. Esteve S.A. | Combinacion de sustancias activas para el tratamiento de la diabetes. |
EP1944295A1 (fr) * | 2007-01-15 | 2008-07-16 | Laboratorios del Dr. Esteve S.A. | Mélanges non racémiques de (R)-N-pipéridinyl-5-(4-chlorophényl)1-1(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide et (S)-N-pipéridinyl-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide |
EP1946778A1 (fr) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Combinaison de substance active pour le traitement des diabètes |
EP1946777A1 (fr) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Composés de pyrazoline substituée pour éviter la prise de poids |
EP1946779A1 (fr) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Combination de pyrazoline substitués et de médicaments contre la dyslipidémie |
EP1947089A1 (fr) * | 2007-01-18 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Polymorphe d'un pyrazoline substitué, sa préparation et utilisation dans le cadre de médicaments |
EA201070019A1 (ru) * | 2007-06-15 | 2010-06-30 | Солвей Фармасьютикалс Б.В. | 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов |
US8410135B2 (en) | 2007-06-15 | 2013-04-02 | Solvay Pharmaceuticals B.V. | 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators |
KR20100072037A (ko) | 2007-09-20 | 2010-06-29 | 애보트 헬스케어 프로덕츠 비.브이. | 칸나비노이드 cb₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1h)-피라졸 |
EP2042175A1 (fr) * | 2007-09-21 | 2009-04-01 | Laboratorios del Dr. Esteve S.A. | Ligands du récepteur CB1 au traitement de l'obésité |
AR071487A1 (es) * | 2008-04-23 | 2010-06-23 | Solvay Pharm Bv | Derivados de (5r)-1,5-diaril-4,5-dihidro-1h-pirazol-3-carboxamidina que tienen actividad antagonista cb1 |
JP6272626B2 (ja) | 2012-11-13 | 2018-01-31 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体媒介性化合物 |
US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
WO2014208939A1 (fr) * | 2013-06-28 | 2014-12-31 | Hanmi Pharm. Co., Ltd. | Dérivés de 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine à titre d'antagoniste du récepteur cb1 des cannabinoïdes, leur procédé de préparation, et composition pharmaceutique les contenant |
WO2015172059A1 (fr) * | 2014-05-09 | 2015-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dérivés pyrazole et leur utilisation comme médiateurs des récepteurs aux cannabinoïdes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0543930A1 (fr) * | 1990-08-17 | 1993-06-02 | E.I. Du Pont De Nemours And Company | Pyrazolines, pyrazolidines et hydrazines arthropodicides |
JPH07504658A (ja) * | 1992-03-02 | 1995-05-25 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 殺節足動物性アミド類 |
JP2004500401A (ja) * | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 |
EP1373216B1 (fr) * | 2001-03-22 | 2004-12-15 | Solvay Pharmaceuticals B.V. | Derives de 4,5-dihydro-1h-pyrazole ayant une activite d'antagoniste de cb 1 |
HUP0402113A3 (en) * | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
SI1429761T1 (sl) * | 2001-09-21 | 2007-02-28 | Solvay Pharm Bv | Novi 4,5-dihidro-1h-pirazolni derivati s cb1-antagonisticno aktivnostjo |
-
2005
- 2005-01-27 CN CNB2005800034967A patent/CN100563651C/zh not_active Expired - Fee Related
- 2005-01-27 SI SI200530419T patent/SI1713475T1/sl unknown
- 2005-01-27 WO PCT/EP2005/050339 patent/WO2005074920A1/fr active IP Right Grant
- 2005-01-27 RU RU2006131132/04A patent/RU2360904C2/ru not_active IP Right Cessation
- 2005-01-27 KR KR1020067017475A patent/KR20060131861A/ko not_active Application Discontinuation
- 2005-01-27 CA CA002552940A patent/CA2552940A1/fr not_active Abandoned
- 2005-01-27 JP JP2006550185A patent/JP4693787B2/ja not_active Expired - Fee Related
- 2005-01-27 AT AT05707857T patent/ATE402697T1/de active
- 2005-01-27 MX MXPA06008593A patent/MXPA06008593A/es active IP Right Grant
- 2005-01-27 ES ES05707857T patent/ES2311972T3/es active Active
- 2005-01-27 BR BRPI0507005-8A patent/BRPI0507005A/pt not_active IP Right Cessation
- 2005-01-27 PL PL05707857T patent/PL1713475T3/pl unknown
- 2005-01-27 DK DK05707857T patent/DK1713475T3/da active
- 2005-01-27 PT PT05707857T patent/PT1713475E/pt unknown
- 2005-01-27 AU AU2005210163A patent/AU2005210163B2/en not_active Ceased
- 2005-01-27 DE DE602005008555T patent/DE602005008555D1/de active Active
- 2005-01-27 EP EP05707857A patent/EP1713475B1/fr active Active
-
2006
- 2006-06-26 IL IL176547A patent/IL176547A/en not_active IP Right Cessation
- 2006-08-30 NO NO20063866A patent/NO20063866L/no not_active Application Discontinuation
-
2007
- 2007-05-29 HK HK07105654.9A patent/HK1099688A1/xx not_active IP Right Cessation
-
2008
- 2008-10-27 HR HR20080549T patent/HRP20080549T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PL1713475T3 (pl) | 2009-03-31 |
AU2005210163B2 (en) | 2010-05-13 |
HK1099688A1 (en) | 2007-08-24 |
IL176547A (en) | 2010-06-30 |
IL176547A0 (en) | 2006-10-31 |
ATE402697T1 (de) | 2008-08-15 |
SI1713475T1 (sl) | 2008-12-31 |
RU2360904C2 (ru) | 2009-07-10 |
JP4693787B2 (ja) | 2011-06-01 |
CN100563651C (zh) | 2009-12-02 |
EP1713475B1 (fr) | 2008-07-30 |
WO2005074920A1 (fr) | 2005-08-18 |
BRPI0507005A (pt) | 2007-06-05 |
DK1713475T3 (da) | 2008-12-01 |
KR20060131861A (ko) | 2006-12-20 |
ES2311972T3 (es) | 2009-02-16 |
MXPA06008593A (es) | 2006-08-28 |
EP1713475A1 (fr) | 2006-10-25 |
AU2005210163A1 (en) | 2005-08-18 |
RU2006131132A (ru) | 2008-03-10 |
JP2007519686A (ja) | 2007-07-19 |
DE602005008555D1 (de) | 2008-09-11 |
PT1713475E (pt) | 2008-11-10 |
HRP20080549T3 (en) | 2008-11-30 |
CN1913885A (zh) | 2007-02-14 |
CA2552940A1 (fr) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063866L (no) | 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. | |
ATE411296T1 (de) | Imidazolinderivate mit cb1-antagonistischer wirkung | |
WO2009016460A8 (fr) | Composés pyrazoles | |
WO2008108378A3 (fr) | Dérivé bicyclique d'oxomorpholine | |
WO2007105058A8 (fr) | Pyrazoles | |
DE602005007350D1 (de) | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors | |
SG153811A1 (en) | Quinazolinone derivatives useful as vanilloid antagonists | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
GEP20125637B (en) | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | |
ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
MX2010009401A (es) | Forma cristalina de derivado de fenilamino pirimidina. | |
MX2009010567A (es) | Derivados de imidazolidinona. | |
WO2009061761A3 (fr) | Amines fongicides | |
DE602006017038D1 (de) | Menthancarbonsäureamidderivate mit kühlenden eigenschaften | |
TW200619201A (en) | Process for the preparation of pyrazoles | |
WO2008019030A3 (fr) | Composés d'azole modifiés en tant qu'agents anti-infectieux | |
TW200612944A (en) | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors | |
TW200640927A (en) | 5,6-Dialkyl-7-aminoazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds | |
MX2007007554A (es) | Oxiarenos sustituidos. | |
TW200608890A (en) | Pesticidal compounds | |
UA84594C2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists | |
WO2006126074A3 (fr) | Derives heterocycliques | |
TH73885A (th) | อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่ถูกแทนที่สามที่ที่ 1,3,5 ที่มีการออกฤทธิ์ cb1-แอนตาโกนิสติก | |
TH60792A (th) | อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่มี cb1-แอนแทกโกนีสทิค แอคทิวิทีอย่างมาก | |
TH94288A (th) | อนุพันธ์ 1,1-ไดออกโซ-ไธโอมอร์โฟลินิล อินโดลิล เมทธาโนน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |